NDAOPHTHALMICSOLUTION/DROPS
Approved
Apr 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
6/8 — Strong
PROLENSA (bromfenac sodium) by Bausch + Lomb is anti-inflammatory drug (nsaid) that has anti-inflammatory activity. Approved for macular edema, diabetic retinopathy. First approved in 2013.
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROLENSA (bromfenac sodium) is an ophthalmic nonsteroidal anti-inflammatory drug (NSAID) approved in 2013 for reducing postoperative inflammation and ocular pain following cataract surgery. It works by inhibiting cyclooxygenase (COX) 1 and 2 enzymes, thereby blocking prostaglandin synthesis, which are key mediators of intraocular inflammation. Administered as eye drops, PROLENSA addresses a critical post-surgical need in ophthalmology where rapid inflammation control directly impacts patient comfort and surgical outcomes.
$0.1BPart D
7.5 years to LOEMechanism of Action
anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase (COX) 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of…
Indications (2)
Worked on PROLENSA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.